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Abstract
Purpose To prospectively compare SIRT and DEB-
TACE for treating hepatocellular carcinoma (HCC).
Methods From 04/2010–07/2012, 24 patients with histo-
logically proven unresectable N0, M0 HCCs were ran-
domized 1:1 to receive SIRT or DEB-TACE. SIRT could
be repeated once in case of recurrence; while, TACE was
repeated every 6 weeks until no viable tumor tissue was
detected by MRI or contraindications prohibited further
treatment. Patients were followed-up by MRI every
3 months; the final evaluation was 05/2013.
Results Both groups were comparable in demographics
(SIRT: 8males/4females, mean age 72 ± 7 years; TACE:
10males/2females, mean age 71 ± 9 years), initial tumor
load (1 patient C25 % in each group), and BCLC (Barce-
lona Clinic Liver Cancer) stage (SIRT: 129B; TACE 19A,
119B). Median progression-free survival (PFS) was
180 days for SIRT versus 216 days for TACE patients
(p = 0.6193) with a median TTP of 371 days versus
336 days, respectively (p = 0.5764). Median OS was
592 days for SIRT versus 788 days for TACE patients
(p = 0.9271). Seven patients died in each group. Causes of
death were liver failure (n = 4 SIRT group), tumor pro-
gression (n = 4 TACE group), cardiovascular events, and
inconclusive (n = 1 in each group).
Conclusions No significant differences were found in
median PFS, OS, and TTP. The lower rate of tumor pro-
gression in the SIRT group was nullified by a greater
incidence of liver failure. This pilot study is the first pro-
spective randomized trial comparing SIRT and TACE for
treating HCC, and results can be used for sample size
calculations of future studies.
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Drug-eluting bead-transarterial chemoembolization
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Introduction
Hepatocellular carcinoma (HCC) is one of the most com-
mon cancers with an annual incidence of around 750.000
per year worldwide [1, 2]. Its incidence is still rising, mainly
due to the increasing numbers of Hepatitis B (HBV) and C
virus (HCV) infections [3]. Unfortunately, the majority of
patients are diagnosed in intermediate or advanced clinical
stages excluding them from potentially curative treatments
like resection, transplantation, or local ablation. According
to the barcelona clinic liver cancer classification (BCLC),
patients with intermediate stage HCC (BCLC stage B)
should undergo transarterial chemoembolization (TACE)
[1, 4, 5]. In intermediate stage HCC, TACE has a proven
survival benefit compared to the best supportive care with
1- and 2-year survivals of 82 and 63 %, respectively [6].
Precision-V study has defined a standardized embolization
technique with drug eluting beads compared to the variety
of different conventional TACE protocols reported in the
literature [7, 8].
During the last few years, selective internal radiotherapy
(SIRT), also referred to as radioembolization, was intro-
duced for HCC as a second-line therapy in case of TACE
failure. One of its main advantages is the reduced number
of treatments needed; therefore, SIRT has potential as a
first-line therapy for patients with intermediate stage HCC
(BCLC stage B) despite its slightly higher costs [9]. Our
impression is that the reduced number of treatment sessions
and the small size of the embolization particles preserve
patency of the tumor feeding arteries. Since this maintains
direct access to the tumor vessels, another local treatment,
e.g., TACE, could still be performed as a second-line
treatment in case of SIRT failure. Randomized data for
HCC treatment using SIRT are not currently available. The
only reports on treatment results are retrospective [10–12],
non-randomized [13], or deal with feasibility of treatment
in advanced HCC, dose-finding, and SIRT-associated
complications [14]. The aim of this randomized pilot study
was to investigate whether SIRT might compare with, or
even have some advantages over, TACE for treating HCC.
Patients and Methods
Study Design
This study was a prospective, single-center, randomized
trial with two parallel treatment groups receiving either
DEB-TACE or SIRT. The trial was conducted on the basis
and principles of ICH-GCP and according to the Declara-
tion of Helsinki in its revised version. The study protocol
(including patient information with consent) and any sub-
stantial amendments were approved by the responsible
Ethics Committee. The study is registered at www.
clinicaltrials.gov as NCT01798160. A literature review in
2010 provided papers on SIRT-associated complications
[15], feasibility of SIRT in advanced patients [16], and
dose finding. The only studies describing the treatment
results of SIRT are retrospective [17] or non-randomized
[13] and investigated an inhomogeneous patient collective
not comparable to stage B patients according to BCLC [4].
Therefore, we finally decided that a reliable power calcu-
lation is not feasible and label this study a pilot study.
Patients
The final study population consisted of 24 patients, 12 in
each group of patients (mean age in SIRT group 71.8 ±
7.2 years, range, 58–82 years; mean age in TACE group
70.5 years, range 59–87 years). The SIRT group consisted
of eight men and four women, the TACE group comprised
ten men and two women. All patients suffered from his-
tologically proven M0 N0 HCC. The indication for local
tumor treatment was assessed by an interdisciplinary HCC-
tumor board. All patients meeting the inclusion criteria and
eligible for both SIRT and TACE were included (Table 1).
Informed consent was obtained from all individual
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participants included in the study. After stratification
according to tumor load (\25 %/C25 %), patients were
randomized. Treatment allocation was predetermined by an
independent statistician and used a randomized block
design. The final randomization was carried out after
having obtained written informed consent.
Liver MRI
Liver imaging was performed with contrast enhanced MRI
using 3-Tesla scanners (Skyra or Magnetom Trio,
Siemens). Study protocols included: T1w FLASH 2d (in- and
opposed phase), T2w HASTE, DWI, contrast enhanced
dynamic 3d VIBE sequences [start delay after contrast bolus:
0 s (native), 20 s (arterial), 45 s (portal-venous), and 90 s
(equilibrium-Phase)], and a late 2d FLASH phase. Gadolin-
ium-DTPA (Magnevist, Bayer Schering Pharma AG),
0.1 mmol/kg body weight, 2 ml/s, was administered by bolus
injection (Spectris, Medrad) for contrast. Image analysis
was carried out independently by two investigators experi-
enced in cross sectional liver imaging. This analysis was
followed by a consensus reading to obtain the final diagnosis.
CT Scan
To rule out extrahepatic tumor spread, all patients under-
went CT of the thorax and abdomen (256-row iCT, Phi-
lips Medical Systems) with standard acquisition
parameters: abdomen: 120 kV, mAs according to auto-
matic dose modulation, slice thickness 1 and 3 mm, con-
trast bolus 120 ml Iomeprol (Imeron 400 Altana Pharma)
using a bolus injector (Injektron CT2, Medtron) with a
flow rate of 4 ml/s, and a start delay by bolus trigger
150 HE—native, 10 s (arterial) and 45 s (portal-venous);
thorax: 120 kV, mAs according to automatic dose modu-
lation, slice thicknesses 1 and 3 mm.
SIRT Procedure
The SIRT procedure has been extensively described [18].
Patients underwent preparative intervention with angiog-
raphy of the hepatic artery and protective coiling of side
branches (e.g., gastroduodenal artery, right gastric artery).
Afterwards, 150 MBq 99mTc-MAA was injected into the
liver arteries using the same catheter position chosen for
the scheduled SIRT session. Calculation of the hepato-
pulmonary shunt fraction and tracer distribution was
evaluated with subsequent planar images and SPECT
imaging (MAA-scan) [14, 16, 19]. Patients were then dis-
charged and re-admitted for SIRT.
SIRT was performed using resin-based 90Y loaded mi-
croparticles (SirSpheres, Sirtex Medical). The activity and
dose for 90Y-SirSpheres were calculated according to the
body surface model as suggested by the REBOC expert
panel [20, 21]. SIRT was performed in a lobar approach. In
case of bilobar tumor spread, treatment was split in two
sessions. In these cases, the first treatment was dedicated to
the liver lobe with the greater tumor volume. Treatment of
the contra-lateral lobe was scheduled after 4 weeks to pre-
serve liver function. After each treatment, patients were
monitored for 2 days. Follow-up visits were performed
every 3 months until clinical endpoints were reached. In
cases with local tumor progression and an absence of con-
traindications, SIRT could be repeated once according to the
study protocol. In cases with contraindications, crossover to
TACE was permitted. Patients with crossover from SIRT to
TACE were not censored.
TACE Procedure
TACE was performed using drug-eluting beads (DC
Beads, 100-300 lm, Terumo) loaded with a maximum
Table 1 Inclusion/exclusion criteria
Inclusion criteria
C18 years
HCC, proven by histology or according to EASL criteria
Intermediate stage HCC (stage B according to BCLC)
At least one measurable lesion in magnetic resonance imaging
(MRI)
Tumor load B50 %
Preserved liver function (Child Pugh A – B7)
Exclusion criteria
Patients feasible for curative treatment (e.g., resection or local
ablation)
Previous TACE or SIRT
Chemotherapy during the last 4 weeks
Child Pugh stage C
BCLC stage C
ECOG Performance Status [0
Tumor involvement [50 % of the liver
Extrahepatic tumor
Serum bilirubin [2.0 mg/dl; serum albumin 2.8 g/dl, serum
creatinine [2 mg/dl; leukocytes \3,000/ml; thrombocytes
\50,000/ml
Clinically apparent ascites (ascites only in CT/MRI is no
exclusion criteria)
Esophageal bleeding during the last 3 months
Hepatic encephalopathy
Transjugular intrahepatic portosystemic shunt (TIPS)
Infiltration or occlusion of the portal vein
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dose of 150 mg Doxorubicin per session [22]. The beads
were administrated super selectively at the level of seg-
mental and subsegmental arteries until stasis was reached
(embolization endpoint). In patients with multilocular
tumor spread or bilobar disease preventing a selective
approach, a less selective embolization technique was used
and each session was limited to one liver lobe according to
the discretion of the investigator. In those cases, the contra-
lateral lobe was treated after 4 weeks. TACE was repeated
every 6 weeks until no more viable tumor was detected by
MRI [7, 23]. Then, follow-up visits were performed every
3 months until clinical endpoints were reached. In cases
with local tumor progression and an absence of contrain-
dications, TACE could be repeated. If contraindications
appeared, crossover to SIRT was possible according to the
protocol. Patients with crossover from TACE to SIRT were
not censored. Follow-up was carried out every 3 months
and included physical examination, blood tests, documen-
tation of adverse-/serious adverse-events (AE/SAE), and
MRI of the liver.
Outcome Measures
Survival is not only limited by tumor progression, but also
by deterioration of liver function as a result of the under-
lying liver cirrhosis. Therefore, the primary endpoint was
progression-free-survival (PFS) as it includes local treat-
ment effects as well as death by deteriorating liver function
[5, 24]. Local tumor response was measured according to
the modified criteria for response evaluation in solid
tumors (mRECIST) [25]. Overall survival (OS) is also
influenced by secondary treatment strategies following
SIRT/TACE failure; therefore, it was applicable as a sec-
ondary endpoint. Time to progression (TTP) and time-to-
locally-non-treatable-progression (nTTP) were also calcu-
lated. The TTP was defined as the time at which progres-
sion was evident according to the definitions of mRECIST
in follow-up MRI or CT (extrahepatic disease). The nTTP
was defined as the time at which local tumor progression of
the liver could no longer be treated with the assigned
treatment regime (SIRT or TACE) because of contraindi-
cations (e.g., laboratory findings), technical problems (e.g.,
occluded access artery), and/or occurrence of an extrahe-
patic tumor, preventing a continued local treatment
approach.
The causes of deaths were analyzed with respect to the
clinical aspect of the patients, laboratory tests, and imaging
data. Death due to tumor progression was determined when
tumor load was considerably increased, with replacement
of normal liver tissue and/or invasion of large vessels
possibly associated with liver failure and/or significant
extrahepatic tumor spread. Vice versa, death due to liver
failure was determined when liver function decreased (e.g.,
extensive ascites and need for paracentesis, increasing
bilirubin levels, and impaired coagulation status) in the
absence of an increasing tumor load.
Statistical Analysis
Statistical analysis system (SAS), Version 9.2 (SAS
Institute Inc.) was used for analysis, which was purely
exploratory. Statistical analysis was done by an indepen-
dent statistician to avoid review bias. Primary and sec-
ondary outcome measures (PFS, OS, TTP, and nTTP) were
compared using the log-rank test. Time-to-event data were
analyzed by the Kaplan–Meier method and descriptive
statistics of all other parameters were provided. The null
hypothesis was that there is no difference in PFS for




Between April 2010 and July 2012, thirty-two patients with
intermediate stage HCC were screened for study inclusion.
Seven of these patients were excluded due to poor liver
function (n = 3), extrahepatic tumor spread in CT (n = 3),
and withdrawal of consent immediately before randomi-
zation (n = 1). Subsequently, 25 patients were random-
ized, 13 to SIRT and 12 to TACE treatment. One SIRT
patient showed significant hepatopulmonary shunting in the
MAA scan and had to be excluded from treatment. Thus,
12 patients were treated in each group. There were no cases
lost to follow up. One patient in the TACE group under-
went liver transplantation 7.5 months after randomization
and was, therefore, censored (Fig. 1). At study entry, there
were no significant differences between groups in patients’
ages and genders, or liver function (Table 2). The size of
target lesions according to mRECIST was not significantly
different between both groups (SIRT: 61.3 ± 36.4 mm,
range 10–134 mm; TACE: 60.8 ± 37.6 mm, range
30–163 mm), nor was the distribution of tumors in the liver
(uni-/bilobar: SIRT 4/8; TACE 5/7), or the distribution of
tumor volume (one patient with C25 % tumor load in each
group; Table 2).
SIRT/TACE procedures and follow-up
SIRT was performed selectively in a lobar approach. SIRT
patients received only one (n = 4) or two treatment ses-
sions (n = 8), with 33.5 ± 6.8 days between sessions,
according to the protocol. The activity of 90Y-SirSpheres
was 1847 ± 504 MBq, with a wide range depending on
M. B. Pitton et al.: SIRT Versus TACE for HCC 355
123
tumor volume and liver function. In TACE patients, the
mean number of treatment sessions was 3.8 ± 2.6 with a
range of 1–10 depending on local tumor response and
patency of the access vessels. The interval between sub-
sequent treatment sessions was 48.2 ± 14.0 days. Embo-
lization was unilobar in five and bilobar in seven patients,
depending on the tumor distribution and local tumor
response evaluated by MRI. The cumulative Doxorubicin
dose was 259.4 ± 158.4 mg with a 150 mg maximum of
Doxorubicin-loaded DC Beads per treatment session.
Follow-up was 435 ± 320 days for SIRT and
404 ± 304 days for TACE and included all events until the
final evaluation date (Table 2).
Outcome
There were no statistically significant differences between
both groups in PFS (180 for SIRT versus 216 days for
TACE, Fig. 2A) and OS (592 days for SIRT vs. 788 days
for TACE, Fig. 2B; Table 3). There was no 30-day mor-
tality in either group. During follow-up, mortality after
SIRT was caused predominantly by liver failure (n = 4)
with only one death due to tumor progression. In the TACE
group, four patients died from tumor progression and only
one due to liver failure. One patient in each group died
from a cardiovascular complication. One patient presented
with progressive heart failure and edema 3 months after the
first TACE. She did not receive repeated TACE because of
an arteriovenous shunt and substantial tumor progression
after the one session. Another patient was re-admitted
7 days after SIRT. She suffered from a pseudoaneurysm of
the femoral artery (access site complication) and a large
retroperitoneal hematoma. The access site was surgically
revised and the hematoma was released. Subsequently, she
developed renal insufficiency and heart failure with the
need for hemodialysis. After several days of dialysis, she
refused continued treatment and died 42 days after SIRT.
For one patient in each group, there was non-conclusive
data on the final cause of death.
There was no significant difference between groups with
respect to TTP (371 days after SIRT versus 336 days after
TACE) and nTTP (488 after SIRT versus 647 days after
TACE) (Table 3). In the SIRT group, no patient had a
repeated SIRT treatment because of contraindications.
* This patient was censored after 7.5 months but not excluded from analysis. 
Assessed for eligibility (n=32) 
Excluded (n=7) 
Not meeting inclusion criteria (n=6) 
Declined to participate (n=1)
)21=n(Analysed
Excluded from analysis (n=0)
Lost to follow-up (n=0) 
Discontinued intervention (n=0) 
Allocated to SIRT (n=13) 
Received allocated intervention (n=12)
Did not receive allocated intervention due to 
significant hepatopulmonary shunting (n=1)
Lost to follow-up (n=0) 
Discontinued intervention due to liver 
transplantation after 7.5months (n=1) * 
Allocated to intervention (n=12) 
Received allocated intervention (n=12)
Did not receive allocated intervention (n=0)
)21=n(Analysed






CONSORT Flow Diagram Fig. 1 Flowchart according to
the CONSORT guidelines
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Fig. 2 A Progression-free-
Survival (PFS) in days
(Progression: PD according to
mRECIST): Treatment (trt) 1
SIRT, Treatment (trt) 2 TACE
B Overall Survival. Treatment
(trt) 1 SIRT, treatment (trt) 2
TACE
Table 2 Patient characteristics and treatment strategy
Patient demographics SIRT TACE
Patients treated (n) 12 12
Male/Female 8/4 10/2
Age (years) 71.8 ± 7.2 (58–82) 70.5 ± 9.0 (59–87)
Etiology of liver cirrhosis
(alcohol/HCV/HBV/cryptogen) 5/5/0/2 5/4/1/3*
Prior curative treatment
Resection/local ablation 3/4 5/1
Tumor burden
SLD** (mm) 61.3 ± 36.4 mm (10–134) 60.8 ± 37.6 mm (30–163)
Tumor volume \ 25 %/C 25 % 11/1 11/1
Tumor grading
G1/G2/G3 6/6/0 6/5/1
AFP (ng/ml) 3308 ± 10204 (6.2–32346***)
Median 14.0
164 ± 529 (2.7–1847***)
Median 7.8
Liver function
Child A/B/C 10/2/0 9/3/0
BCLC A/B 0/12 1/11
Laboratory
Bilirubin (mg/dl) 1.17 ± 0.54 (0.38–2.10) 1.26 ± 0.55 (0.59–2.04)
Albumin (g/l) 34.08 ± 5.57 (28–43) 31.92 ± 4.25 (24–39)
INR 1.11 ± 0.12 (1–1.4) 1.13 ± 0.09 (1–1.3)
Thrombocytes (/nl) 159.83 ± 53.59 (111–265) 156.25 ± .85.03 (59–402)
Leucocytes (/nl) 5.23 ± 1.60 (2.27–8.28) 5.49 ± 1.52 (3.96–8.20)
Treatment strategy
Randomization to treatment (days) 28.8 ± 13.8 (13–56) 15.7 ± 5.9 (4–24)
Treatment session per patient (n) 1.5 ± 0.5 (1–2) 3.8 ± 2.6 (1–10
Interval between treatment sessions (days) 33.5 ± 6.8 (27–42) 48.2 ± 14.0 (19–89)
Uni-/bilobar approach 4/8 5/7
Dose
Total liver dose 1847 ± 504 MBq (1160–2940) 259.4 ± 158.4 mg (87.5–648.5)
Right liver lobe dose 1216 ± 288 MBq (830–1630) 205.4 ± 76.5 mg (144.5–359.5)
Left liver lobe dose 946 ± 250 MBq (590–1460) 126.4 ± 68.4 mg (60–289)
Follow-up (days) 435 ± 320 (77–1024) 404 ± 304 (52–950)
Data given as mean ± SD (range)
* One patient with HBV/HCV co-infection
** SLD sum of longest diameters of target lesions according to mRECIST
*** Extensive AFP level in one patient in each group
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Three of four patients with local tumor progression devel-
oped conditions that predicted liver insufficiency (new
ascites and elevated bilirubin levels [2.0 mg/dl), which
prevented repeated SIRT. These patients received DC-Bead
TACE, as the bilirubin levels were \3 mg/dl and no con-
traindications for TACE were evident. Another patient with
local tumor progression developed an arterioportal shunt,
which was a contraindication for SIRT and TACE.
In the TACE group, 8 out of 12 patients presented with
diverse changes of the tumor feeding arteries. As the number
of TACE procedures increased (median 3.5, range 1–10),
these patients presented with increasing irregularities and
narrowing of vessel walls, or even occlusions. Bypassing
and insufficient reticular networks of collateral vessels
prevented selective access to the tumor nodules and appli-
cation of a sufficient embolization dose. In five of these eight
patients, repeated treatment had to be aborted. In addition,
there was one patient with an iatrogenic dissection of the
celiac trunk that prohibited further catheterization and two
patients with arteriovenous shunts with a myriad of cross-
links preventing all embolization techniques.
After cessation of loco-regional treatment, one patient
received curative liver transplantation (TACE group) and
two received local tumor ablation, one in each group
(Table 4). The patient who underwent liver transplantation
was censored for further statistical calculations. The other
patients with tumor progression received Sorafenib, local
radiation of critical bone metastases, and underwent clini-
cally indicated surgeries (Table 4).
Discussion
This randomized clinical pilot study compared the onco-
logic efficiency of SIRT and TACE in patients with unre-
sectable HCC. The potential risk of vessel damage as a
result of repetitive embolization in TACE seems to be
considerably lower in SIRT due to its smaller particle sizes
and the reduced number of treatment sessions. This, toge-
ther with the much easier application in the right and left
hepatic artery makes it very attractive for the patient
compared to super-selective TACE procedures with longer
intervention times and repeated hospital admissions. The
study protocol was designed to provide data on local tumor
response, treatment associated peri-interventional compli-
cations, and potential side effects concerning liver function
and overall survival. The results of this study might provide
potential study endpoints, sample sizes, and safety aspects
for a confirmatory multicenter study. The inclusion and
exclusion criteria reflect the spectrum of HCC patients at
our University Hospital with some variation in tumor load
(similarly distributed in both groups) and without impaired
liver function. The TACE group served as the control
according to the allocation rules of the BCLC scheme [4].
The relatively small final sample size of 24 (2 9 12)
patients reflects a study limitation.
Current data suggested SIRT was a favorable second-line
treatment for diverse tumors, including HCC, after failure of
standard treatment regimens [6, 11]. The results of this pilot
study demonstrate no differences in the PFS and OS after
SIRT and TACE and no significant statistical differences in
TTP and nTTP. The median survival after TACE found in
this study is comparable to reported survival data after DC-
Bead TACE and represents typical clinical results [26].
However, the reduced number of SIRT treatment sessions
and hospital days might be a significant difference that
reflects an advantage in terms of quality of life [27]. Another
potential advantage of SIRT over TACE is the significantly
reduced harm caused to feeding arteries. The preserved
patency of the tumor feeders allows for repeated transarterial
tumor treatment with any kind of method in case of tumor
progression. However, in the current study, patients with
tumor progression presented with reduced liver function that
prohibited repeated SIRT. A small number of cases crossed-
over to TACE, but without benefit in overall survival. In
addition, a considerable number of patients presented with
occluded feeder arteries after repeated TACE that prevented
direct transarterial access to the tumor and repeated embo-
lizations of any kind.
We were able to differentiate between deaths due to
progressive liver failure versus tumor progression. In all
patients, the cause of death was identified while consider-
ing the clinical course. Death was due to liver failure when
liver function decreased without a respective increase in
Table 3 Outcome measures
Outcome measures SIRT TACE p
PFS 180 (120/414); 266 ± 55 216 (88/355); 237 ± 49 p = 0.6193
OS 592 (192/–); 437 ± 72 788 (178/950); 583 ± 119 p = 0.9271
TTP 371 (132/561); 353 ± 69 336 (91/609); 315 ± 69 p = 0.5764
nTTP 488 (148/925); 490 ± 114 647 (182/–); 416 ± 83 p = 0.9322
The median number of days (Q1/Q3) and mean ± standard errors are shown
PFS Progression-free-Survival, OS overall-survival, TTP time-to-Progression, nTTP time-to-non-treatable-progression
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tumor load and vice versa. The cause of deaths in this study
might impact future interventional techniques. The less
selective application of SirSpheres at the level of lobar
arteries has the advantage of ease and speed of application;
in addition, it is an effective treatment of non-visible
micro-nodules that otherwise might become evident as
recurrences during follow-up, which typically occurs for
patients treated with super-selective TACE. However,
there is an increased risk for secondary liver failure when
one or both liver lobes are treated unselectively. Our data
demonstrated secondary liver insufficiency as the primary
cause of death after SIRT; while, there were considerably
more deaths due to tumor progression in TACE patients.
Radiation induced liver disease (RILD) has already been
reported within 2 months following SIRT [14, 16, 21, 22].
In our patients, fatal liver insufficiencies occurred at 4, 8,
20, and 21 months after SIRT; however, it is not clear
whether this was due to deterioration due to liver cirrhosis
or to radiation induced toxicity beyond 2 months. Thus,
further evaluations should examine whether a more selec-
tive SIRT application could reduce the incidence of liver
failure. However, this would presumably result in a higher
rate of local tumor progression in the non-treated liver
segments, comparable to the super-selective TACE
approach used. Nonetheless, this selective SIRT approach
might require repetitive SIRT treatments.
In conclusion, this randomized pilot study suggests
SIRT and TACE are equivalent in terms of progression-
free survival, overall survival, and TTP in intermediate
stage HCC patients. The lower rate of tumor progression in
the SIRT group was nullified by a greater incidence of liver
failure. The results of this analysis should aid future studies
for clarifying treatment decisions, determining medical
expenses and treatment costs, as well as supplementing the
BCLC scheme.
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